Taro Receives US Patent For Ovide

Taro has received patent covering its Ovide (malathion) lotion, 0.5% (patent no. US 7,560,445) from the US Patent and Trademark Office.

The patent is for a highly pure form of malathion for topical pharmaceutical use and a method of making pure pharmaceutical grade malathion, as well as for a formulation containing the pharmaceutical grade malathion and a method for treating head lice.

In the past year, over 250,000 prescriptions for Ovide (malathion) lotion, 0.5% were filled in the US, making Ovide as one of the major prescript treatment for head lice in the US, said the company.

Taro is engaged in catering the needs of its customers through the discovery, development, manufacturing and marketing of healthcare products.